Page 117 - Genentech News Today

PagerDuty, Inc. , a leader in digital operations management, today announced it will release its financial results for the second quarter fiscal year 2024, ended July 31, 2023, after market close on... -Today at 04:18 pm- MarketScreener

Hans Lee, MD, discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and how these data may inform the future of the multiple myeloma treatment paradigm.

The South San Francisco-based biotech company Genentech will pay penalties over 2021 hazardous waste violations, the Environmental Protection Agency announced...

The FDA’s accelerated-approval process was designed to help people access life-saving drugs. But gaps in communication could mean that people are undergoing treatments known to be ineffective. The FDA’s accelerated-approval process was designed to help people access life-saving drugs. But gaps in communication could mean that people are undergoing treatments known to be ineffective.

/PRNewswire/ -- The "Allogeneic Cell Therapy: Global Market Report 2023-2035" report has been added to ResearchAndMarkets.coms offering. The global allogeneic...

EPA inspectors allegedly found several violations at the companys facility

The U.S. Environmental Protection Agency announced a settlement with Genentech

/PRNewswire/ -- On Thursday, August 17th, 2023, the Black Health Matters Harlem Week Health Summit & Expo will be held at the historic Alhambra Ballroom, 2116...

Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response.

/PRNewswire/ -- The "NASH Treatment & Therapeutics Market Report 2023-2033" report has been added to ResearchAndMarkets.coms offering. The report presents a...